8 recruiting, 4 completed, 4 unknown, 3 withdrawn. 14 Phase 1, 12 Phase 2, 1 Not applicable, 1 Phase 3.
Follow Relapsed Adult AML: new trials by email Literature Review of Relapsed Adult AML trials Research Report on Relapsed Adult AML
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Menin-Inhibitor Targeted Maintenance in AML Revumenib, Placebo - Relapsed Adult AML, Stem Cell Transplant Complications | Phase 2 | Not yet recruiting | Center for International Blood and Marrow Transplant Research | 146 | 2026-12-01 | 2026-06-22 |
| Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT AdaptNK, Fludarabine, Cyclophosphamide - Relapsed Adult AML, Refractory AML | Phase 1 / Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 18 | 2026-05-08 | 2026-05-19 |
| Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19 CAR-T cell therapy - Relapsed Adult AML | Phase 1 | Recruiting | University Hospital, Lille | 5 | 2025-07-10 | 2025-12-05 |
| Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia zelenirstat - Relapsed Adult AML | Phase 1 | Recruiting | Pacylex Pharmaceuticals | 35 | 2025-03-03 | 2025-03-10 |
| Tislelizumab with Azacitidine in the Treatment of R/R AML Aza, tislelizumab - Refractory AML, Relapsed Adult AML | Phase 1 / Phase 2 | Withdrawn | Institute of Hematology & Blood Diseases Hospital, China | 2024-10-05 | 2024-09-19 | |
| Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia Navitoclax Dose Level -1, Navitoclax Dose Level 0, Navitoclax Dose Level 1 - Relapsed Adult AML, Refractory AML | Phase 1 | Withdrawn | Medical College of Wisconsin | 2024-08-31 | 2024-08-13 | |
| CLL-1 CAR-NK Cells for Relapsed/Refractory AML anti-CLL-1 CAR NK cells - Relapsed Adult AML, Refractory AML | Phase 1 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 24 | 2024-04-01 | 2025-09-30 |
| Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia AzaCITIDine Oral Tablet, Xospata - AML, Adult, Refractory AML | Phase 2 | Recruiting | French Innovative Leukemia Organisation | 33 | 2024-01-13 | 2025-03-24 |
| Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT Plerixafor - Relapsed Adult ALL, Relapsed Adult AML | Phase 2 | Unknown | The First Hospital of Jilin University | 28 | 2023-09-01 | 2023-11-21 |
| Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients Lintuzumab-Ac225, Venetoclax, Azacitidine - Acute Myeloid Leukemia, Relapsed Adult AML | Phase 1 / Phase 2 | Withdrawn | Actinium Pharmaceuticals | 2023-03-01 | 2023-07-20 | |
| Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia Specialty Palliative Care, Primary Palliative Care - Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia | Not applicable | Recruiting | Massachusetts General Hospital | 2300 | 2022-06-01 | 2025-07-25 |
| Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML venetoclax combining chidamide and azacitidine (VCA) - Leukemia, Myeloid, Acute, Relapsed Adult AML | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 30 | 2022-01-12 | 2025-09-11 |
| New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia CAHAG regimen, Placebo regimen - Acute Myeloid Leukemia, Refractory Acute Leukemia | Phase 2 | Active not recruiting | The First Affiliated Hospital of Soochow University | 21 | 2021-09-01 | 2026-03-19 |
| A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE Refractory AML, Relapsed Adult AML | Completed | French Innovative Leukemia Organisation | 177 | 2021-07-05 | 2023-05-24 | |
| PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine,Cytarabine, G-CSF for Refractory or Relapsed AML Visilizumab - Immunotherapy, Refractory Leukemia | Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 30 | 2021-05-01 | 2021-12-03 |
| Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML LP-108, LP-108 and azacitidine - AML/MDS, CMML | Phase 1 | Completed | Newave Pharmaceutical Inc | 32 | 2020-07-06 | 2026-01-23 |
| Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX) Venetoclax Oral Tablet - Relapsed Adult AML, Refractory AML | Phase 1 / Phase 2 | Completed | Technische Universität Dresden | 55 | 2020-04-06 | 2026-09-02 |
| Natural Killer Cell (CYNK-001) Infusions in Adults with AML CYNK-001 - Leukemia, Leukemia, Myeloid | Phase 1 | Terminated | Celularity Incorporated | 27 | 2020-03-12 | 2024-12-12 |
| Venetoclax and Lintuzumab-Ac225 in AML Patients Lintuzumab-Ac225, Venetoclax, Spironolactone - Acute Myeloid Leukemia, Relapsed Adult AML | Phase 1 / Phase 2 | Unknown | Actinium Pharmaceuticals | 38 | 2020-01-15 | 2023-08-04 |
| Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia Gemtuzumab Ozogamicin 3 mg/m^2, Gemtuzumab Ozogamicin 2 mg/m^2, Pracinostat - 45 mg - Relapsed Adult AML | Phase 1 | Completed | Medical College of Wisconsin | 14 | 2019-05-24 | 2022-06-30 |
Showing 20 of 23. Sign in to see all of them.
Leukemia, Myeloid, Acute (23) · Recurrence (4) · Leukemia (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Hematologic Neoplasms (2) · Hematologic Diseases (1) · Hodgkin Disease (1) · Leukemia, Myeloid (1) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Neoplasm, Residual (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Hemic and Lymphatic Diseases (23) · Hematologic Diseases (22) · Leukemia, Myeloid (22) · Neoplasms (22) · Neoplasms by Histologic Type (22) · Leukemia (20) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Disease Attributes (4) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Leukemia, Lymphoid (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Bone Marrow Diseases (2)
Azacitidine (6) · venetoclax (5) · Cytarabine (2) · Cladribine (1) · Cyclophosphamide (1) · Filgrastim (1) · Gemtuzumab (1) · Granulocyte Colony-Stimulating Factor (1) · Homoharringtonine (1) · Immunotherapy, Adoptive (1) · Infusions, Intravenous (1) · Interleukin-2 (1) · Mitoxantrone (1) · SB939 compound (1) · Spironolactone (1)
Actinium Pharmaceuticals (2) · French Innovative Leukemia Organisation (2) · Medical College of Wisconsin (2) · The First Affiliated Hospital of Soochow University (2) · Agios Pharmaceuticals, Inc. (1) · Aptose Biosciences Inc. (1) · Celularity Incorporated (1) · Center for International Blood and Marrow Transplant Research (1) · Ciusss de L'Est de l'Île de Montréal (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Masonic Cancer Center, University of Minnesota (1) · Massachusetts General Hospital (1) · Newave Pharmaceutical Inc (1) · Pacylex Pharmaceuticals (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1)
United States (9) · China (6) · France (3) · Germany (2) · Spain (2) · Australia (1) · Canada (1) · New Zealand (1) · South Korea (1)
Avinash Desai, MD (2) · Areej El-Jawahri, MD (1) · Bing Xu (1) · Denis-Claude Roy, MD PhD (1) · Guru Subramanian Guru Murthy, MD, MS (1) · Han Yue, Ph.D (1) · Ibrahim Yakoub-Agha, MD,PhD (1) · Jennifer Temel, MD (1) · Long Su, PhD (1) · Naval Daver, MD (1) · Naveen Pemmaraju (1) · Sameem Abedin, MD (1) · Sharmila Koppisetti, M.D (1)
PMID 33347715, PMID 38715059, PMID 39665627, PMID 41791831
2023 (2)